A Phase 2 interventional study of miltefosine plus intralesional pentamidine in Leishmaniasis, Cutaneous, sponsored by Jonathan Berman. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-02-27.
Sponsored by Jonathan Berman · Phase 2, Interventional, and Treatment
Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5). Efficacy and tolerance parameters were assessed. Efficacy was assessed at 1, 3, and 6 months post therapy. Tolerance was assessed on each day therapy was administered.
Exclusion Criteria:
miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
Drug: miltefosine plus intralesional pentamidine
miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
Lesion size
area of lesion
Time frame: 6 months post therapy
adverse effects at site
pain, erythema, edema
Time frame: days 1, 3, 5 of therapy
systemic adverse effects
gastrointestinal side effects
Time frame: days 1 to 28 of therapy
No study locations are listed for this record.
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.